Erasca Financials - Benzinga

Erasca Inc

ERASNASDAQ

Trade with Public

Trade with Public

$18.03

-1.46-7.49%

At close: Aug 28, 5:00 PM EST

$18.69

0.663.66%

After Hours: Aug 28, 6:31 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Erasca Financials

Erasca (ERAS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the

Benzinga Newsdesk

Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials

Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.

Vandana Singh

PRO
Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.22) by 172.73 percent. This is a 445.45 percent decrease over losses of $(0.11) per share from the

Benzinga Newsdesk

PRO
Erasca Q4 EPS $(0.10), Inline

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.

Benzinga Newsdesk

PRO
Erasca Q3 EPS $(0.11), Inline

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Erasca Q2 EPS $(0.12) Misses $(0.11) Estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 58.62 percent increase over losses of $(0.29) per share from the same

Benzinga Newsdesk